Post-Transplant Urinary Transglutaminase 2 Is a Potent Biomarker to Predict Kidney Allograft Inflammation or Fibrosis.
1Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Meeting: 2017 American Transplant Congress
Abstract number: A127
Keywords: Fibrosis, Kidney transplantation
Session Information
Session Name: Poster Session A: Diagnostics/Biomarkers Session I
Session Type: Poster Session
Date: Saturday, April 29, 2017
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall D1
Transglutaminase type 2 (TG2) is an extracellular matrix crosslinking enzyme with a pivotal role in kidney fibrosis. We tested the hypothesis that quantification of urinary TG2 is a noninvasive method to estimate the severity of kidney allograft fibrosis. We prospectively collected urine specimens from nine cadaveric kidney transplant recipients post-transplant one day, seven days, one month, three months, and six months. In addition, kidney allograft tissue specimens at zero-day and six-months post-transplant were sampled to analyze the correlation of urinary TG2 and kidney allograft fibrosis. Six recipients (the aggravation group) had borderline cellular rejection or chronic score (ct+ci) increase at six-months protocol biopsy compared with those at zero-day biopsy. Mean level of urinary TG2 in the aggravation group was significantly lower compared with that in other three recipients (the control group) at post-transplant one day (0.0496±0.0556 vs 0.2393±0.0624, p=0.004) and one month (0.0090±0.0078 ng/ml 0.1642±0.0886 ng/ml, p=0.026). In addition, the difference in chronic scores between zero-day and six-months biopsies was inversely correlated with urinary TG2 level at post-transplant one day (R2=0.729, p=0.04). In the aggravation group, double immunofluorescent staining revealed that TG2 intensity was significantly upregulated and colocalization of TG2/heparin sulfate proteoglycan was prominent, usually around tubular structures. In conclusion, urinary TG2 in early post-transplant periods is a potent biomarker for kidney allograft inflammation or fibrosis.
CITATION INFORMATION: Shin S, Wee Y.-M, Choi M, Cho Y, Go H, Kim Y, Han D. Post-Transplant Urinary Transglutaminase 2 Is a Potent Biomarker to Predict Kidney Allograft Inflammation or Fibrosis. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Shin S, Wee Y-M, Choi M, Cho Y, Go H, Kim Y, Han D. Post-Transplant Urinary Transglutaminase 2 Is a Potent Biomarker to Predict Kidney Allograft Inflammation or Fibrosis. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/post-transplant-urinary-transglutaminase-2-is-a-potent-biomarker-to-predict-kidney-allograft-inflammation-or-fibrosis/. Accessed December 12, 2024.« Back to 2017 American Transplant Congress